Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650619 · ClinicalTrials.gov registry record
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
A clinical trial of Focal Segmental Glomerulosclerosis and Minimal Change Disease, sponsored by University of Michigan.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT05650619 is a study of Focal Segmental Glomerulosclerosis and Minimal Change Disease that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 300 participants, above the 221-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05650619, a study of Focal Segmental Glomerulosclerosis and Minimal Change Disease, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes. The purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.
Conditions Studied
Interventions
- OTHER Biospecimen collection
- OTHER Data collection
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05650619
The ClinicalTrials.gov registry entry for NCT05650619 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 221-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (36% higher). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen collection is the first listed.
NCT05650619 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05650619 about?
NCT05650619 is a clinical study titled "Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease". The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment h...
What is the current status of trial NCT05650619?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-12-08. Estimated completion is 2026-12.
What conditions does trial NCT05650619 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD.
What interventions are being tested in trial NCT05650619?
The interventions under investigation include: Biospecimen collection (OTHER), Data collection (OTHER).
Who is sponsoring clinical trial NCT05650619?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05650619 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 2
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 3
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
RECRUITING · NA
-
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
RECRUITING · Phase 2
-
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.